Healthcare M&A » By The Online Investor Staff, updated Fri., Dec. 6, 12:32 PM
Recent mergers and acquisitions in the Healthcare M&A category.
Slide #43. Mallinckrodt Pharmaceuticals — Questcor Pharmaceuticals
| Acquirer: |
Mallinckrodt Pharmaceuticals (MNK) |
| Acquiree: |
Questcor Pharmaceuticals (QCOR) |
| Details: |
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a high-growth biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion. The transaction was unanimously approved by the Boards of Directors of both companies. Subject to customary closing conditions, the transaction is currently expected to be completed in the third calendar quarter of 2014. |
Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.
MNK SEC Filing Email Alerts Service
Open the MNK Page at The Online Investor »
Mallinckrodt develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare disease in areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology, immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. Co. operates its business in two reportable segments: Specialty Brands, which markets branded pharmaceutical products for autoimmune and rare diseases; and Specialty Generics and Amitiza, which provides specialty generic drugs, active pharmaceutical ingredients, and Amitiza® (lubiprostone), a product in the gastrointestinal market.
MNK SEC Filing Email Alerts Service
Open the QCOR Page at The Online Investor »
Quotes delayed 20 minutes
|
